Gleave ME - Search Results

1

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

Miyake H, Tolcher A, Gleave ME. Miyake H, et al. Among authors: gleave me. Cancer Res. 1999 Aug 15;59(16):4030-4. Cancer Res. 1999. PMID: 10463603

2

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].

Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M. Bruchovsky N, et al. Urologe A. 1995 Sep;34(5):389-92. Urologe A. 1995. PMID: 7483155 Review. German.

3

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: gleave me. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

4

Control of tumor progression by maintenance of apoptosis.

Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M. Bruchovsky N, et al. Prostate Suppl. 1996;6:13-21. Prostate Suppl. 1996. PMID: 8630223 Review.

5

Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.

Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Rabbani F, et al. Among authors: gleave me. Cancer. 1996 Aug 1;78(3):480-6. doi: 10.1002/(SICI)1097-0142(19960801)78:3<480::AID-CNCR15>3.0.CO;2-V. Cancer. 1996. PMID: 8697394

6

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD. Sato N, et al. Among authors: gleave me. J Steroid Biochem Mol Biol. 1996 May;58(2):139-46. doi: 10.1016/0960-0760(96)00018-0. J Steroid Biochem Mol Biol. 1996. PMID: 8809195

7

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. Sato N, et al. Among authors: gleave me. Cancer Res. 1997 Apr 15;57(8):1584-9. Cancer Res. 1997. PMID: 9108464

8

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1997 May;157(5):1727-30. J Urol. 1997. PMID: 9112514

9

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.

Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. Gleave ME, et al. J Cell Biochem. 1998 Jun 1;69(3):271-81. J Cell Biochem. 1998. PMID: 9581866

10

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Gleave M, et al. Eur Urol. 1998;34 Suppl 3:37-41. doi: 10.1159/000052297. Eur Urol. 1998. PMID: 9854195 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

667 results

Search Page

Filters